- Home
- TRML vs CHPT Comparison
TRML vs CHPT Comparison
Compare TRML & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- CHPT
- Stock Information
- Founded
- TRML 2021
- CHPT 2007
- Country
- TRML United States
- CHPT United States
- Employees
- TRML N/A
- CHPT N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- CHPT Industrial Specialties
- Sector
- TRML Health Care
- CHPT Consumer Discretionary
- Exchange
- TRML Nasdaq
- CHPT Nasdaq
- Market Cap
- TRML 509.8M
- CHPT 468.9M
- IPO Year
- TRML N/A
- CHPT N/A
- Fundamental
- Price
- TRML $14.45
- CHPT $0.61
- Analyst Decision
- TRML Strong Buy
- CHPT Hold
- Analyst Count
- TRML 6
- CHPT 10
- Target Price
- TRML $45.20
- CHPT $1.69
- AVG Volume (30 Days)
- TRML 360.6K
- CHPT 22.3M
- Earning Date
- TRML 03-13-2025
- CHPT 03-04-2025
- Dividend Yield
- TRML N/A
- CHPT N/A
- EPS Growth
- TRML N/A
- CHPT N/A
- EPS
- TRML N/A
- CHPT N/A
- Revenue
- TRML N/A
- CHPT $417,083,000.00
- Revenue This Year
- TRML $363.93
- CHPT $14.08
- Revenue Next Year
- TRML N/A
- CHPT $26.64
- P/E Ratio
- TRML N/A
- CHPT N/A
- Revenue Growth
- TRML N/A
- CHPT N/A
- 52 Week Low
- TRML $11.87
- CHPT $0.56
- 52 Week High
- TRML $29.79
- CHPT $2.44
- Technical
- Relative Strength Index (RSI)
- TRML 41.51
- CHPT 37.13
- Support Level
- TRML $16.39
- CHPT $0.56
- Resistance Level
- TRML $17.36
- CHPT $0.71
- Average True Range (ATR)
- TRML 1.03
- CHPT 0.05
- MACD
- TRML -0.21
- CHPT 0.00
- Stochastic Oscillator
- TRML 3.46
- CHPT 28.00
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.